Panbela Therapeutics Inc PBLA shares are trading higher after the company announced the publication of preclinical and clinical data from studies of CPP-1X (also known as α-Difluoromethylornithine (DFMO) or Eflornithine) in recent-onset type 1 diabetes (T1D). 

Data published in the journal Cell Reports Medicine investigated the mechanism of polyamines and polyamine inhibition by CPP-1X on β cell stress that plays a role in the onset of type 1 diabetes in in vitro and ex vivo models. 

Results showed that DFMO treatment may preserve β cell function, reflected by C-peptide levels in patients with T1D through the modulation of urinary polyamines, particularly putrescine. 

From the Phase 1 dose range finding study of CPP-1X in patients with recent onset T1D, CPP-1X was well tolerated, and a dose-dependent inhibition of ODC was observed. 

An exploratory secondary analysis showed that at the two highest dose levels, treatment with CPP-1X stabilized C-peptide areas under the curve compared to placebo. 

When assessing immune cell populations, there were no differences between the placebo and CPP-1X patients.

Results from these studies suggest that CPP-1X is a safe, oral treatment option that may improve β cell function and/or survival in recent onset T1D.

Price Action: PBLA shares are up 31.80% at $1.05 on the last check Thursday.